Produção Nacional
Revisado por pares
Barriers to global pharmacometrics: educational challenges and opportunities across the globe
2023; Nature Portfolio; Volume: 12; Issue: 6 Linguagem: Inglês
10.1002/psp4.12940
ISSN2163-8306
AutoresRobin Michelet, Linda B. S. Aulin, Jens Markus Borghardt, Teresa Dalla Costa, Paolo Denti, Manuel Ibarra, Guangda Ma, Bernd Meibohm, Goonaseelan Pillai, Stephan Schmidt, Stefanie Hennig, Charlotte Kloft,
Tópico(s)Health Systems, Economic Evaluations, Quality of Life
ResumoCPT: Pharmacometrics & Systems PharmacologyEarly View PERSPECTIVEOpen Access Barriers to global pharmacometrics: educational challenges and opportunities across the globe Robin Michelet, Corresponding Author Robin Michelet [email protected] orcid.org/0000-0002-5485-607X Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany qPharmetra LLC, Nijmegen, The Netherlands Correspondence Robin Michelet, Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany. Email: [email protected]Search for more papers by this authorLinda B. S. Aulin, Linda B. S. Aulin Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, GermanySearch for more papers by this authorJens M. Borghardt, Jens M. Borghardt orcid.org/0000-0001-7000-9308 Research DMPK, Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, GermanySearch for more papers by this authorTeresa Dalla Costa, Teresa Dalla Costa orcid.org/0000-0001-9227-2991 Pharmaceutical Sciences Graduate Program, Federal University of Rio Grande do Sul, Porto Alegre, BrazilSearch for more papers by this authorPaolo Denti, Paolo Denti orcid.org/0000-0001-7494-079X Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South AfricaSearch for more papers by this authorManuel Ibarra, Manuel Ibarra orcid.org/0000-0002-0484-6367 Department of Pharmaceutical Sciences, Faculty of Chemistry, Universidad de la República, Montevideo, UruguaySearch for more papers by this authorGuangda Ma, Guangda Ma Department of Pharmacology & Clinical Pharmacology, The University of Auckland, Auckland, New ZealandSearch for more papers by this authorBernd Meibohm, Bernd Meibohm orcid.org/0000-0003-3923-3648 Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USASearch for more papers by this authorGoonaseelan (Colin) Pillai, Goonaseelan (Colin) Pillai Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa CP+ Associates GmbH, Basel, Switzerland Phamacometrics Africa NPC, Cape Town, South AfricaSearch for more papers by this authorStephan Schmidt, Stephan Schmidt orcid.org/0000-0002-4998-1167 Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USASearch for more papers by this authorStefanie Hennig, Stefanie Hennig orcid.org/0000-0001-5972-3711 Certara, Inc., Princeton, New Jersey, USA School of Clinical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia Department of Clinical Pharmacy, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, GermanySearch for more papers by this authorCharlotte Kloft, Charlotte Kloft Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, GermanySearch for more papers by this author Robin Michelet, Corresponding Author Robin Michelet [email protected] orcid.org/0000-0002-5485-607X Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany qPharmetra LLC, Nijmegen, The Netherlands Correspondence Robin Michelet, Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany. Email: [email protected]Search for more papers by this authorLinda B. S. Aulin, Linda B. S. Aulin Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, GermanySearch for more papers by this authorJens M. Borghardt, Jens M. Borghardt orcid.org/0000-0001-7000-9308 Research DMPK, Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, GermanySearch for more papers by this authorTeresa Dalla Costa, Teresa Dalla Costa orcid.org/0000-0001-9227-2991 Pharmaceutical Sciences Graduate Program, Federal University of Rio Grande do Sul, Porto Alegre, BrazilSearch for more papers by this authorPaolo Denti, Paolo Denti orcid.org/0000-0001-7494-079X Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South AfricaSearch for more papers by this authorManuel Ibarra, Manuel Ibarra orcid.org/0000-0002-0484-6367 Department of Pharmaceutical Sciences, Faculty of Chemistry, Universidad de la República, Montevideo, UruguaySearch for more papers by this authorGuangda Ma, Guangda Ma Department of Pharmacology & Clinical Pharmacology, The University of Auckland, Auckland, New ZealandSearch for more papers by this authorBernd Meibohm, Bernd Meibohm orcid.org/0000-0003-3923-3648 Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USASearch for more papers by this authorGoonaseelan (Colin) Pillai, Goonaseelan (Colin) Pillai Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa CP+ Associates GmbH, Basel, Switzerland Phamacometrics Africa NPC, Cape Town, South AfricaSearch for more papers by this authorStephan Schmidt, Stephan Schmidt orcid.org/0000-0002-4998-1167 Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USASearch for more papers by this authorStefanie Hennig, Stefanie Hennig orcid.org/0000-0001-5972-3711 Certara, Inc., Princeton, New Jersey, USA School of Clinical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia Department of Clinical Pharmacy, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, GermanySearch for more papers by this authorCharlotte Kloft, Charlotte Kloft Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, GermanySearch for more papers by this author First published: 24 March 2023 https://doi.org/10.1002/psp4.12940 Stefanie Hennig and Charlotte Kloft shared senior authorship. AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL During the past three decades, pharmacometrics has developed considerably and gained recognition globally and across disciplines, causing the demand of well-trained pharmacometricians to outweigh the availability.1 Thus, high-quality and widespread education of pharmacometricians is key. A symposium and panel discussion titled "Training of the Next Generation of Pharmacometric Talent Around the World" at the third World Conference on Pharmacometrics (WCoP2022, Cape Town) explored this issue and resulted in the perspective presented here. Pharmacometrics is a complex and multidisciplinary scientific field with strong interplay between academia and industry. As a consequence, pharmacometrics education is associated with both opportunities and challenges,2, 3 prompting unique initiatives and networks across the globe.4-6 Approximately 15 years after starting a number of educational initiatives,7-9 their impact needs to be discussed with respect to the initial purpose and how to move forward from them. Therefore, a symposium was held at WCoP2022, a hybrid event with approximately 300 participants worldwide, which aimed to share different perspectives on pharmacometric education and to obtain a global perspective. THE SYMPOSIUM: INTERNATIONAL PERSPECTIVES AND AUDIENCE INPUT The symposium consisted of six talks where international speakers with diverse backgrounds, all of which are actively training pharmacometric talents, presented their experiences and perspectives on the required skillsets of future pharmacometricians, education and training concepts, and related challenges and opportunities, followed by a panel discussion with contributions from the audience. The talks and discussion made clear that different challenges and opportunities for pharmacometrics training exist across the globe, with some being specific for certain localities and others being consistent worldwide, showing high intra- and interregional differences. A depiction of the main ones is provided in Figure 1 and more details, including the recordings of all talks, representing successful examples, can be found in the Supplementary Material. In the remainder of this perspective, we aim to synthesize the insights of the symposium into three clearly grouped challenges and opportunities which need tailored approaches: the movement of human capital, the multidisciplinary nature and the unbalanced spread of pharmacometrics across regions. FIGURE 1Open in figure viewerPowerPoint The local and global challenges for pharmacometrics training and education. Green dots with arrows represent locations of the speakers of the World Conference on Pharmacometrics symposium, and colored circles represent the different challenges and opportunities to tackle them, which are further discussed in the text. The ratio of academic to geographic movement of human capital is depicted semantically using two colors in the same circle. Challenges and opportunities related to the movement of human capital ("brain-drain") Pharmacometricians trained in low- and middle-income countries often move to the European Union or United States, leading to a brain-drain and difficulties in establishing not only larger teaching and training groups in these countries but also a stronger local pharmacometrics community ("geographic brain-drain"). The use of remote working opportunities should in theory allow a dampening of this geographic brain-drain, especially in an in silico field such as pharmacometrics. However, as echoed by the panelists during the symposium and the panel discussion (Supplementary Material), in practice this is not (yet) the case and both pharmaceutical companies and consulting companies hire mostly from EU, USA and Oceania or require working visas at these locations. Furthermore, academic centers, regardless of location, encounter increasing difficulty to attract and retain researchers at the post-doctoral, early to mid-career level and even senior faculty level. Not re-filling open positions as already observed presents a global threat eventually leading to fewer academic centers that offer opportunities for the next generation in the long-term. This in turn makes teaching and training activities and sustainability more challenging, leading to a loss of critical mass to sustain teaching ("academic brain-drain"; Figure 2). Both brain-drains especially the case in LMIC, where a critical mass of pharmacometricians is not always present. A minimum expression of a critical mass is needed to generate human resources and capabilities at a local level, and furthermore to connect the local community with the rest of the field globally. As long as this is not achieved, the above-described brain-drain will be the status quo in those countries, preventing the local communities to significantly supply the world with human resources. Therefore, aiming for trained pharmacometricians developing the discipline outside of Europe and US, e.g. by joint efforts such as Pharmacometrics Africa, RedIF and PAGANZ should be seen as part of the way forward. However, a stronger collaboration between academia and industry could be an opportunity for local development of pharmacometricians within an academic setting. Initiatives such as internships, industry mentors, on-site visits and projects using shared data (e.g., also from preclinical studies) are potential ways in which students and mid-level researchers can strive for a "best-of-two-worlds" approach. Academia and consulting companies are currently fostering this approach by "sharing" and offering part-time employees training and supervising opportunities. This might reduce the need to move away from their local or academic position. This stronger collaboration could also lead to increased mentoring support from industry in the form of e.g. industry mentors, expert knowledge sharing and providing guidance to students and early-career scientists. Indeed, sharing expertise back to academia is one of the essential points how industry partners can contribute towards moving forward from the status quo. Lastly, financial and logistic support for student scholarships, attendance of conferences, or fund academic-industry exchanges, especially from industry, for the training of the next generation of pharmacometrics talents might stimulate dedicated programs to stay active or grow capacity and attract talents to academic positions, which might make a (part-time) academic career more attractive for scientists. FIGURE 2Open in figure viewerPowerPoint Imbalanced flow of pharmacometricians between academia, and pharmaceutical industry and consultancy, leading to a possible decrease in newly trained pharmacometric talent. Challenges and opportunities related to pharmacometrics as a multidisciplinary field Due to the multidisciplinary nature of pharmacometrics, there are two key challenges to exploring the potential of yet not identified next-generation talents: undergraduate students with the right skill set and mind-set need to be attracted background-specifically to the discipline and opportunities of pharmacometrics that are mostly new for them. Background-specific material could be developed to this end in a global effort. The curriculum of any academic training program should, especially at the beginning, acknowledge this diversity in backgrounds. Yet, all involved will quickly learn and see the diversity as an advantage. A critical aspect in developing the multidisciplinary pharmacometric mindset in young scientists is the understanding of fundamental principles of pharmacokinetics, pharmacodynamics, biopharmaceutics and pathophysiology. Dedicated modules in these basic sciences could be part of international training programs and included as recommended or mandatory parts of graduate programs. What can be left for on-the-job training might differ for students from different scientific backgrounds. Furthermore, the required expertise will strongly depend on the area in which a pharmacometrician works. Therefore, to build a one-size-fits-all university educational program is challenging (e.g., clinical, preclinical, or authorities). Instead, education could focus on a curriculum based on a desired set of core competencies. Multidisciplinary and specialized (under-) graduate courses could be developed in consensus with the pharmacometrics community and recognized by a professional international body, which would help to attract interested students from various disciplines early on. Our colleagues have provided more details about the practical implementation of such an approach from a US perspective. The aforementioned multidisciplinary mind-set allows pharmacometricians to be "good model communicators" who can efficiently translate between different disciplines, and identify the most impactful question for pharmacometric analyses.10 Therefore, training to communicate results, implications, and assumptions of pharmacometric analyses should be considered equally important as methodological training. Good model communicators are pivotal for a sustainable future of pharmacometrics and to facilitate the move from an expert discipline to a fully embedded discipline within project teams. Challenges and opportunities related to the unbalanced spread of pharmacometrics The pharmacometrics community is relatively small but globally spread. A combination of local, international, and global collaborations could lead to optimal use of the unique insights across the world and allow students access to a large international network. International organizations such as the International Society of Pharmacometrics and WCoP are facilitating and spearheading global networking and collaboration initiatives. Furthermore, in past years, hybrid and remote working formats have been shown feasible for a pharmacometrics career. Especially smaller research groups and consulting companies have taken the opportunity to recruit from anywhere on the globe while allowing pharmacometric talents to work in their original country. This might improve talent retention and also allow better collaboration between remote-working pharmacometricians and local academic groups to foster local development of pharmacometric groups and strengthen the connection in the pharmacometrics community. ROADMAP FOR NEXT STEPS Training the next generation of pharmacometricians is a challenging task. Until now, it has been tackled through varying approaches across the globe, showcasing unique local challenges that might (only) be solved on a global scale. For example, the practical implementation of such an approach from a US perspective is provided in a companion paper to this one (under review). Indeed, joint efforts for continuous and sustainable development of pharmacometrics are crucial: overarching umbrella initiatives, for example, led by one of the hosts of the large pharmacometrics meetings, such as PAGE, ACoP, or WCoP, connect local initiatives such as the networks and training programs here (RedIF, PMXAfrica, PharMetrX) and others (Asian Pharmacometrics Network, PAGANZ) and share their strengths while mitigating their challenges and weaknesses. This could lead to a centralized location where interested students can learn about pharmacometrics and which training opportunities exist within reach, i.e. an expansion of the ISoP website with all pharmacometric training programs and networks could be a good starting point. Stronger collaboration between academia and the pharmaceutical industry in the form of internships, scholarships, and exchanges could foster the sustainable growth of pharmacometric skills in early career scientists across the globe. Furthermore, financial and mentoring support also of the pharmaceutical industry of pharmacometricians-in-training in the form of scholarships, academic-industry exchanges and sponsored conference attendance could, especially in LMIC, increase the retention of these young talents locally. As a next step, an open debate across the pharmacometrics community on how to tackle the identified challenges would be beneficial. We invite the readers and the global pharmacometrics community to reach out with their point of view, ideas, or suggestions in an open debate to achieve this goal. FUNDING INFORMATION SH was partly supported by the Alexander von Humboldt Foundation, Germany. CONFLICT OF INTEREST STATEMENT The authors declared no competing interests for this work. DISCLOSURE As an Associate Editor for CPT: Pharmacometrics and Systems Pharmacology, Stefanie Hennig was not involved in the review or decision process for this article. Supporting Information Filename Description psp412940-sup-0001-Supinfo.docxWord 2007 document , 23 KB Data S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Romero K, Corrigan B, Tornoe CW, et al. Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success. J Clin Pharmacol. 2010; 50(9): 9S- 19S. 2Rowland Yeo K, Hennig S, Krishnaswami S, et al. CPT: Pharmacometrics & Systems Pharmacology – inception, maturation, and future vision. CPT Pharmacometrics Syst Pharmacol. 2021; 10(7): 649- 657. 3Brouwer KLR, Schmidt S, Floren LC, Johnson JA. Clinical pharmacology education – the decade ahead. Clin Pharmacol Therap. 2020; 107(1): 37- 39. doi:10.1002/cpt.1652 4Hennig S, Hannam JA, Kirkpatrick CMJ, et al. Pharmacometrics in Australasia—twenty years of population approach group of Australia and New Zealand. CPT: Pharm Syst Pharmacol. 2019; 8(10): 701- 704. doi:10.1002/psp4.12460 5Pillai G, Davies G, Denti P, et al. Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa. CPT: Pharm Syst Pharmacol. 2013; 2(8): 1- 4. doi:10.1038/psp.2013.45 6Ibarra M, Dalla Costa T, Schaiquevich P, et al. Iberoamerican Pharmacometrics network congress 2018 report: fostering modeling and simulation approaches for drug development and regulatory and clinical applications in Latin America. CPT: Pharm Syst Pharmacol. 2019; 8(4): 197- 200. doi:10.1002/psp4.12387 7Holford N, Karlsson MO. Time for quantitative clinical pharmacology: a proposal for a pharmacometrics curriculum. Clin Pharmacol Ther. 2007; 82(1): 103- 105. 8Vlasakakis G, Comets E, Keunecke A, et al. White paper: landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation. CPT Pharmacometrics Syst Pharmacol. 2013; 2(5): e40. 9Zhang T, Cho CR, Bonate PL. Perspectives on training quantitative systems pharmacologists. CPT: Pharm Syst Pharmacol. 2022; 11(6): 669- 672. doi:10.1002/psp4.12783 10Bonate PL. Be a Model Communicator: and Sell your Models to Anyone [Internet]. Peter Bonate; 2014. Available from: https://books.google.com/books/about/Be_a_Model_Communicator.html?hl=de&id=ro8nrgEACAAJ Early ViewOnline Version of Record before inclusion in an issue FiguresReferencesRelatedInformation
Referência(s)